Investigational drug · Phase 2
Test Product HY07121
Also called: HY0007-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Safety, Tolerability, Efficacy.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Test Product HY07121"
First trial start
2024
Oct 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Test Product HY07121", any sponsor or status.
Conditions studied
As listed on its trial records.
- Safety
- Tolerability
- Efficacy
Largest trials
Live from ClinicalTrials.gov: studies naming "Test Product HY07121" as an intervention, largest first.
Sichuan Huiyu Pharmaceutical Co., LtdIndustry
NCT06639256 · 258 participants (planned) · Start Oct 24, 2024 · Primary completion May 26, 2027
Drug: Test Product HY07121 · For: Safety; Tolerability; Efficacy
Sites: Jinan, China
- Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid TumorsNot yet recruiting
Sichuan Huiyu Pharmaceutical Co., LtdIndustry
NCT07789327 · 254 participants (planned) · Start Sep 8, 2026 · Primary completion Apr 2028
Drug: Test Product HY07121 for Injection (Subcutaneous); Test Product HY07121 for Injection (Subcutaneous) · For: Safety; Tolerability; Efficacy
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Safety
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- IRL757Phase 21 trial
Integrative Research Laboratories AB · PARKINSON DISEASE (Disorder), Apathy, Safety
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.